Evidence map›Paper›PMID 24862368›Full record

ArticlePsychopharmacology2014

Effects of corticotrophin-releasing factor receptor 1 antagonists on amyloid-β and behavior in Tg2576 mice.

Hongxin Dong, Shirlene Wang, Ziling Zeng, Fei Li, Janitza Montalvo-Ortiz, Christopher Tucker, Shahzad Akhtar, Jingshan Shi, Herbert Y Meltzer, Kenner C Rice and 1 more

Open access · greenAbstract read
In one paragraph

Article in Psychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 45 citations in OpenAlex.

  1. Sex differences in neuromodulatory subcortical systems and their implications for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  2. Experimental laboratory models as tools for understanding modifiable dementia risk.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Hongxin DongDepartment of Psychiatry and Behavioral Sciences, Feinberg School Medicine, Northwestern University, 303 E. Chicago Ave, Chicago, IL, 60611, USA, h-dong@northwestern.edu.
Shirlene Wang
Ziling Zeng
Fei Li
Janitza Montalvo-Ortiz
Christopher Tucker
Shahzad Akhtar
Jingshan Shi
Herbert Y Meltzer
Kenner C Rice
John G Csernansky
Northwestern University · USZunyi Medical University · CNCenter for Global Development · USNational Institute on Drug Abuse · USShandong University · CN

Funding

Medicinal Chemistry of Drugs Acting on Biogenic Amine ReceptorsZIADA000532 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI RICE, KENNER · 2009 to 2020
$4.5M
Medicinal Chemistry of Drugs Acting on CRH ReceptorsZIADA000528 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI RICE, KENNER · 2009 to 2018
$1.8M
Stress, Glucocorticoids and Alzheimer DiseaseR01AG025824 · NIA · WASHINGTON UNIVERSITY · PI CSERNANSKY, JOHN G · 2005 to 2009
$1.6M
Aging and Antipsychotic Efficacy - Epigenetic MechanismsR21MH100919 · NIMH · NORTHWESTERN UNIVERSITY AT CHICAGO · PI DONG, HONGXIN · 2013 to 2014
$425k
Intramural NIH HHS ZIA DA000532NIA NIH HHS R01 AG025824NIMH NIH HHS R21 MH100919
6 · The paper itself

Abstract

rationalePrevious studies indicate that psychosocial stressors could accelerate amyloid-β (Aβ) levels and accelerate plaque deposition in mouse models of Alzheimer disease (AD). Stressors enhanced the release of corticotrophin-releasing factor (CRF), and exogenous CRF administration mimicked the effects of stress on Aβ levels in mouse models of AD. However, whether CRF receptor 1 (CRF1) antagonists could influence the stress-induced acceleration of an AD-like process in mouse models has not been well studied.

objectiveWe sought to examine whether CRF1 antagonists inhibit the effects of isolation stress on tissue Aβ levels, Aβ plaque deposition, and behaviors related to anxiety and memory in Tg2576 mice, and to investigate the molecular mechanism underlying such effects.

methodsCohorts of Tg2576 mouse pups were isolated or group-housed at 21 days of age, and then the subgroups of these cohorts received daily intraperitoneal injections of the CRF1 antagonists, antalarmin or R121919 (5, 10, and 20 mg/kg), or vehicle for 1 week. Other cohorts of Tg2576 mouse pups were isolated or group-housed at 21 days of age, and then at 4 months of age, subgroups of these mice were administered antalarmin (20 mg/kg) or vehicle in their drinking water for 6 months. Finally, cultured primary hippocampal neurons from regular Tg2576 pups (P0) were incubated with CRF (0.1, 1, and 10 nM), antalarmin (100 nM) or H-89 (1 μM) for 48 h. Brain tissues or cultured neurons were collected for histological and biochemical analyses, and behavioral measures were collected in the cohorts of mice that were chronically stressed.

resultsAdministration of antalarmin at 20 mg/kg dose for 1 week significantly reduced Aβ1-42 levels in isolation stressed mice. Administration of antalarmin for 6 months significantly decreased plasma corticosterone levels, tissue Aβ1-42 levels, and Aβ plaque deposition in the brain and blocked the effects of isolation stress on behaviors related to anxiety and memory. Finally, incubation of neurons with 100 nM antalarmin inhibited the ability of 10 nM CRF to increase Aβ1-42 levels and protein kinase A IIβ expression. The effect of CRF1 on Aβ1-42 levels was also diminished by treatment with H-89, a c-AMP/PKA inhibitor.

conclusionsThese results suggest that CRF1 antagonists can slow an AD-like process in Tg2576 mice and that the c-AMP/PKA signaling pathway may be involved in this effect.

Indexed as

Alzheimer DiseaseAmyloid beta-Protein PrecursorAnimalsCorticotropin-Releasing HormoneCRF Receptor, Type 1Cyclic AMPCyclic AMP-Dependent Protein KinasesDisease Models, AnimalHippocampusMaleMemoryMiceMice, TransgenicNeuronsPlaque, AmyloidPyrimidinesAmyloid beta-Protein PrecursorantalarminCorticotropin-Releasing HormoneCRF Receptor, Type 1Cyclic AMPCyclic AMP-Dependent Protein KinasesPyrimidinesPyrrolesR 121919Receptors, Corticotropin-Releasing Hormone

Identifiers

PMID24862368
PMCPMC4233002
OpenAlexW1989767966

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.